calcitonin has been researched along with Hyperparathyroidism* in 8 studies
3 trial(s) available for calcitonin and Hyperparathyroidism
Article | Year |
---|---|
Effects of nasal calcitonin on bone mineral density following parathyroidectomy in patients with primary hyperparathyroidism.
To investigate whether nasal salmon calcitonin (CT; 200 U/day) given in addition to calcium helps to restore the bone mass after parathyroidectomy (PTX) in patients with primary hyperparathyroidism (PHPT).. Twenty patients with PHPT were enrolled after successful PTX and received 1 g calcium per os daily for 1 year. They were randomly assigned either to nasal CT (CT group) or to no treatment. The bone mass was measured using dual-energy X-ray absorptiometry at multiple sites.. Eight patients in each group completed the study. After 12 months, the bone mass increased significantly at whole-body level and at lumbar spine in both groups, increased at hip and epiphyses of tibia or radius in the CT group only, and did not change at diaphyses of tibia and radius in either group.. Bone mass increases after PTX for PHPT in patients receiving oral calcium. CT may help to restore the bone mass at sites of the appendicular skeleton, where trabecular bone predominates. Topics: Administration, Intranasal; Biomarkers; Bone Density; Calcitonin; Calcium; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperparathyroidism; Male; Middle Aged; Parathyroidectomy; Postoperative Period | 2003 |
Comparison of low-dose intramuscular and intravenous salcatonin in the treatment of primary hyperparathyroidism.
The treatment of hypercalcaemia with low-dose salcatonin (100 U/d), administered either as a single intramuscular bolus or as a continuous intravenous infusion for five days, was examined in two groups of 10 patients with primary hyperparathyroidism, in a randomized open parallel study. Both the peak (0.31 +/- 0.035 mmol/L v 0.13 +/- 0.034 mmol/L) and overall (0.073 +/- 0.016 mmol/L v 0.018 +/- 0.016 mmol/L) hypocalcaemic responses were greater in the infusion group. The peak reduction in serum calcium occurred on day 2 of treatment after which there was a progressive attenuation of response. All the differences between the two methods of administration wer due to renal rather than bony effects of salcatonin. Possible causes of progressive resistance to treatment included reductions in sodium excretion and serum phosphate. It is concluded that low-dose salcatonin administered as a continuous infusion was more effective than the same dose given as a bolus. The kidney played a pivotal role both in the cause of the hypercalcaemia and in the response to treatment, including the rapid development of resistance which limits the use of salmon calcitonin in primary hyperparathyroidism to short-term reduction of serum calcium. Topics: Alkaline Phosphatase; Calcitonin; Calcium; Creatinine; Humans; Hypercalcemia; Hyperparathyroidism; Infusions, Intravenous; Injections, Intramuscular; Parathyroid Hormone; Phosphates; Random Allocation | 1992 |
Salmon calcitonin treatment by nasal spray in primary hyperparathyroidism.
The hypocalcemic and hypophosphatemic effect of salmon calcitonin (sCT) given by intranasal (i.n.) spray to 12 patients with histological confirmed primary hyperparathyroidism (1 degree HPT) was studied. The concentration of ionized calcium in whole blood (B-Ca++), serum phosphate (S-P), magnesium (S-Mg), plasma sCT (Pl-sCT), and endogenous CT (hCT) was followed during five 24-hour periods with at least three days between. After period I (control day), 100 IU sCT was given intramuscularly (i.m.) in period II. In periods III-V, either 110, 200, or 400 IU of sCT were given intranasally (i.n.) in randomized order. Although B-Ca++ decreased from the baseline value with all four sCT treatments and at 4.5 hour on the control day (p less than 0.05-0.001), the i.n. sCT treatments had no significant hypocalcemic effect, as the change of the area under the B-Ca++ curve (delta AUC B-Ca++) for the three i.n. treatments was not significantly different from the control period (p less than 0.001, ANOVA). Only the i.m. injection of calcitonin had a calcium-lowering effect (p less than 0.001, ANOVA). Three subjects were considered nonresponders with a decrease in B-Ca++ less than 0.06 mmol/L. S-P decreased within three hours after 200 IU sCT i.n. and 100 IU i.m., but the S-Mg levels showed no consistent changes. The area under the curve for the Pl-sCT levels did not correlate with delta AUC B-Ca++ except for i.m. given sCT.(ABSTRACT TRUNCATED AT 250 WORDS) Topics: Administration, Intranasal; Adult; Aged; Analysis of Variance; Calcitonin; Calcium; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperparathyroidism; Magnesium; Male; Middle Aged; Phosphates; Radioimmunoassay | 1991 |
5 other study(ies) available for calcitonin and Hyperparathyroidism
Article | Year |
---|---|
Recurrent pancreatitis induced by hyperparathyroidism in pregnancy.
As primary hyperparathyroidism affects mainly middle-aged and elderly women, it is an infrequent finding during gestation and breastfeeding. To date, less than 200 pregnant patients with primary hyperparathyroidism diagnosed during pregnancy have been described. Like in other disorders of the parathyroid gland, the recognition of primary hyperparathyroidism during pregnancy and lactation may be difficult, as clinical symptoms are not specific, while laboratory findings may be masked by some typical pregnancy-induced changes in calcium and phosphate homeostasis. If remains untreated, the disease may result in serious clinical implications for the mother and fetus. Most authors consider surgery within the second trimester of pregnancy as the treatment of choice in this group of patients.. In our paper, we discuss the case of a 35-year-old female with a history of recurrent acute pancreatitis and recurrent abortions. As the patient declined surgery, conservative management with calcitonin was started and continued throughout the rest of pregnancy, and led to giving birth to the infant whose only health problem was transient hypocalcemia.. The described case shows that conservative management, if started respectively early and conducted on the basis of a patient's condition, may effectively reduce increased perinatal and maternal morbidity and mortality in pregnant women declining surgery. Topics: Abortion, Habitual; Adenoma; Adult; Calcitonin; Calcium Gluconate; Female; Humans; Hypercalcemia; Hyperparathyroidism; Infant, Newborn; Pancreatitis; Parathyroid Neoplasms; Pregnancy; Pregnancy Complications; Recurrence | 2011 |
Studies on in vivo and in vitro release of intact parathyroid hormone using a new two-site immunochemiluminometric assay.
Topics: Adenoma; Adult; Aged; Calcitonin; Calcium; Female; Fluorescent Antibody Technique; Humans; Hypercalcemia; Hyperparathyroidism; Hyperplasia; In Vitro Techniques; Kidney Failure, Chronic; Luminescent Measurements; Male; Middle Aged; Parathyroid Glands; Parathyroid Hormone; Parathyroid Neoplasms | 1988 |
Improved differential diagnosis of hypercalcemia by hypocalcemic stimulation of parathyroid hormone secretion.
Topics: Calcitonin; Calcium; Diagnosis, Differential; Edetic Acid; Humans; Hypercalcemia; Hyperparathyroidism; Hypocalcemia; Parathyroid Hormone; Reference Values | 1988 |
[Effects of the administration of exogenous calcitonin in dialysis patients. Preliminary study].
Topics: Adult; Aged; Calcitonin; Female; Humans; Hyperparathyroidism; Male; Middle Aged; Parathyroid Hormone; Renal Dialysis | 1985 |
Changes in plasma bone GLA protein during treatment of bone disease.
Bone Gla protein (BGP) was measured in the plasma by radioimmunoassay (RIA) during treatment of 59 patients with bone diseases including Paget's disease (N = 9), primary hyperparathyroidism (N = 25), chronic renal failure (N = 20), and cancer involving bone (N = 5). Plasma BGP was increased above normal in all patients. BGP decreased in the patients with Paget's disease following the acute and chronic administration of salmon calcitonin. Plasma BGP was higher in women then in men with primary hyperparathyroidism. Following parathyroidectomy, BGP decreased in both sexes but the decrease was significant in women only. Plasma BGP was increased in patients with renal osteodystrophy and did not change after hemodialysis. In the patients with bone cancer, plasma BGP decreased during treatment of the attendant hypercalcemia with salmon calcitonin. Although plasma BGP and serum alkaline phosphatase (AP) levels were generally correlated in these studies, there were examples of dissociation between the two. The measurement of plasma BGP appears to provide a specific index of bone metabolism that may in some circumstances be more sensitive than serum alkaline phosphatase measurement. However, further studies are necessary to establish the clinical value of plasma BGP measurement by RIA in the management of patients with bone diseases. Topics: Alkaline Phosphatase; Bone and Bones; Bone Diseases; Bone Neoplasms; Calcitonin; Calcium-Binding Proteins; Chronic Kidney Disease-Mineral and Bone Disorder; Female; Humans; Hyperparathyroidism; Male; Osteitis Deformans; Osteocalcin; Parathyroid Glands; Radioimmunoassay; Renal Dialysis; Vitamin K | 1982 |